Cargando…

Using machine learning and big data to explore the drug resistance landscape in HIV

Drug resistance mutations (DRMs) appear in HIV under treatment pressure. DRMs are commonly transmitted to naive patients. The standard approach to reveal new DRMs is to test for significant frequency differences of mutations between treated and naive patients. However, we then consider each mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Blassel, Luc, Tostevin, Anna, Villabona-Arenas, Christian Julian, Peeters, Martine, Hué, Stéphane, Gascuel, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425536/
https://www.ncbi.nlm.nih.gov/pubmed/34437532
http://dx.doi.org/10.1371/journal.pcbi.1008873
_version_ 1783749865664151552
author Blassel, Luc
Tostevin, Anna
Villabona-Arenas, Christian Julian
Peeters, Martine
Hué, Stéphane
Gascuel, Olivier
author_facet Blassel, Luc
Tostevin, Anna
Villabona-Arenas, Christian Julian
Peeters, Martine
Hué, Stéphane
Gascuel, Olivier
author_sort Blassel, Luc
collection PubMed
description Drug resistance mutations (DRMs) appear in HIV under treatment pressure. DRMs are commonly transmitted to naive patients. The standard approach to reveal new DRMs is to test for significant frequency differences of mutations between treated and naive patients. However, we then consider each mutation individually and cannot hope to study interactions between several mutations. Here, we aim to leverage the ever-growing quantity of high-quality sequence data and machine learning methods to study such interactions (i.e. epistasis), as well as try to find new DRMs. We trained classifiers to discriminate between Reverse Transcriptase Inhibitor (RTI)-experienced and RTI-naive samples on a large HIV-1 reverse transcriptase (RT) sequence dataset from the UK (n ≈ 55, 000), using all observed mutations as binary representation features. To assess the robustness of our findings, our classifiers were evaluated on independent data sets, both from the UK and Africa. Important representation features for each classifier were then extracted as potential DRMs. To find novel DRMs, we repeated this process by removing either features or samples associated to known DRMs. When keeping all known resistance signal, we detected sufficiently prevalent known DRMs, thus validating the approach. When removing features corresponding to known DRMs, our classifiers retained some prediction accuracy, and six new mutations significantly associated with resistance were identified. These six mutations have a low genetic barrier, are correlated to known DRMs, and are spatially close to either the RT active site or the regulatory binding pocket. When removing both known DRM features and sequences containing at least one known DRM, our classifiers lose all prediction accuracy. These results likely indicate that all mutations directly conferring resistance have been found, and that our newly discovered DRMs are accessory or compensatory mutations. Moreover, apart from the accessory nature of the relationships we found, we did not find any significant signal of further, more subtle epistasis combining several mutations which individually do not seem to confer any resistance.
format Online
Article
Text
id pubmed-8425536
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84255362021-09-09 Using machine learning and big data to explore the drug resistance landscape in HIV Blassel, Luc Tostevin, Anna Villabona-Arenas, Christian Julian Peeters, Martine Hué, Stéphane Gascuel, Olivier PLoS Comput Biol Research Article Drug resistance mutations (DRMs) appear in HIV under treatment pressure. DRMs are commonly transmitted to naive patients. The standard approach to reveal new DRMs is to test for significant frequency differences of mutations between treated and naive patients. However, we then consider each mutation individually and cannot hope to study interactions between several mutations. Here, we aim to leverage the ever-growing quantity of high-quality sequence data and machine learning methods to study such interactions (i.e. epistasis), as well as try to find new DRMs. We trained classifiers to discriminate between Reverse Transcriptase Inhibitor (RTI)-experienced and RTI-naive samples on a large HIV-1 reverse transcriptase (RT) sequence dataset from the UK (n ≈ 55, 000), using all observed mutations as binary representation features. To assess the robustness of our findings, our classifiers were evaluated on independent data sets, both from the UK and Africa. Important representation features for each classifier were then extracted as potential DRMs. To find novel DRMs, we repeated this process by removing either features or samples associated to known DRMs. When keeping all known resistance signal, we detected sufficiently prevalent known DRMs, thus validating the approach. When removing features corresponding to known DRMs, our classifiers retained some prediction accuracy, and six new mutations significantly associated with resistance were identified. These six mutations have a low genetic barrier, are correlated to known DRMs, and are spatially close to either the RT active site or the regulatory binding pocket. When removing both known DRM features and sequences containing at least one known DRM, our classifiers lose all prediction accuracy. These results likely indicate that all mutations directly conferring resistance have been found, and that our newly discovered DRMs are accessory or compensatory mutations. Moreover, apart from the accessory nature of the relationships we found, we did not find any significant signal of further, more subtle epistasis combining several mutations which individually do not seem to confer any resistance. Public Library of Science 2021-08-26 /pmc/articles/PMC8425536/ /pubmed/34437532 http://dx.doi.org/10.1371/journal.pcbi.1008873 Text en © 2021 Blassel et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Blassel, Luc
Tostevin, Anna
Villabona-Arenas, Christian Julian
Peeters, Martine
Hué, Stéphane
Gascuel, Olivier
Using machine learning and big data to explore the drug resistance landscape in HIV
title Using machine learning and big data to explore the drug resistance landscape in HIV
title_full Using machine learning and big data to explore the drug resistance landscape in HIV
title_fullStr Using machine learning and big data to explore the drug resistance landscape in HIV
title_full_unstemmed Using machine learning and big data to explore the drug resistance landscape in HIV
title_short Using machine learning and big data to explore the drug resistance landscape in HIV
title_sort using machine learning and big data to explore the drug resistance landscape in hiv
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425536/
https://www.ncbi.nlm.nih.gov/pubmed/34437532
http://dx.doi.org/10.1371/journal.pcbi.1008873
work_keys_str_mv AT blasselluc usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv
AT tostevinanna usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv
AT villabonaarenaschristianjulian usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv
AT peetersmartine usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv
AT huestephane usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv
AT gascuelolivier usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv
AT usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv